These authors contributed equally to this work.
Interference of E2-2-mediated effect in endothelial cells by FAM96B through its limited expression of E2-2
Version of Record online: 2 AUG 2011
© 2011 Japanese Cancer Association
Volume 102, Issue 10, pages 1808–1814, October 2011
How to Cite
Yang, W., Itoh, F., Ohya, H., Kishimoto, F., Tanaka, A., Nakano, N., Itoh, S. and Kato, M. (2011), Interference of E2-2-mediated effect in endothelial cells by FAM96B through its limited expression of E2-2. Cancer Science, 102: 1808–1814. doi: 10.1111/j.1349-7006.2011.02022.x
- Issue online: 28 SEP 2011
- Version of Record online: 2 AUG 2011
- Accepted manuscript online: 1 JUL 2011 11:04AM EST
- (Received March 10, 2011/Revised April 11, 2011; April 26, 2011; June 20, 2011/Accepted June 23, 2011/Accepted manuscript online July 1, 2011/Article first published online August 2, 2011)
Fig. S1. Expression of E2-2 mRNA upon ALK6 activation.
Fig. S2. Effect of vascular endothelial growth factor (VEGF) on expression of FAM96B.
Fig. S3. Effect of FAM96B on expression of c-Myc protein.
Fig. S4. Effect of proteasome inhibitors on FAM96B-mediated decrease of E2-2 protein.
Fig. S5. Effect of a lysosome inhibitor on FAM96B-mediated decrease of E2-2 protein.
Table S1. Polymerase chain reaction primers to amplify mouse cDNAs.
|CAS_2022_sm_fS1.TIF||136K||Supporting info item|
|CAS_2022_sm_fS2.TIF||125K||Supporting info item|
|CAS_2022_sm_fS3.TIF||99K||Supporting info item|
|CAS_2022_sm_fS4.TIF||133K||Supporting info item|
|CAS_2022_sm_fS5.TIF||143K||Supporting info item|
|CAS_2022_sm_tS1.TIF||73K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.